Cell-based therapy for bronchopulmonary dysplasia in preterm infants

A report in the Canadian Journal of Physiology and Pharmacology by MICYRN’s Thierry Lacaze, Martin Offringa (KidsCAN Trials) and CHEO’s Mireille Guillot and Bernard Thébaud provides the outputs of a workshop held to enhance the design of a phase II trial of stem cells for babies at risk for Bronchopulmonary dysplasia (BPD), with a focus on the population to target and the outcomes to measure in such a trial. Click here for the full article.

Andy Rudy